Caresyntax, a vendor-neutral precision surgery platform, is pleased to announce raising a total commitment of $180 million through a series C extension and growth debt expansion round.

Caresyntax是一家供应商中立的精准手术平台，它很高兴地宣布，通过C系列延期和增长债务扩展回合，将筹集1.8亿美元的总承诺。

Investors in the $180 million round include Symbiotic Capital, MTIP AG, BIONIQ Capital, PFM Health Sciences, Pictet Alternative Advisors, surgical.ai, BlackRock Innovation Capital, Aescuvest, Optum Ventures, Cure Capital, Relyens Group, Vesalius Biocapital, Lauxera Capital, Plug & Play Growth Fund, and ProAssurance Corp.

这轮1.8亿美元的投资者包括Symbiotic Capital、MTIP AG、BIONIQ Capital、PFM Health Sciences、Pictet Alternative Advisors、surgical.ai、贝莱德创新资本、Aescuvest、Optum Ventures、Cure Capital、Relyens Group、Vesalius Biocapital、Lauxera Capital、即插即用增长基金和ProAssurance Corp。

The financing comprises $80M of equity and up to $100M of growth debt facility..

融资包括8000万美元的股权和高达1亿美元的增长债务融资。。

Caresyntax is transforming surgery by implementing a scalable, end-to-end software and AI platform. The platform is medical grade, interoperable, and allows the capture and use of novel data and applications to enhance surgical precision and patient safety. Caresyntax serves over 30,000 surgical professionals across more than 3,000 operating rooms worldwide, delivering automation and actionable insights to hospitals, medical device companies, and insurance groups..

Caresyntax正在通过实施可扩展的端到端软件和AI平台来改变手术。该平台是医疗级的，可互操作的，并允许捕获和使用新的数据和应用程序，以提高手术精度和患者安全。Caresyntax为全球3000多个手术室的30000多名外科专业人员提供服务，为医院、医疗器械公司和保险集团提供自动化和可行的见解。。

Himani Bhalla, Chief Investment Officer at Symbiotic Capital stated, “Symbiotic is thrilled to support Caresyntax in its mission to enhance surgical outcomes through its innovative platform, delivering benefits to stakeholders throughout the healthcare ecosystem. We were impressed with Caresyntax’s growth across hospitals, medtechs, and insurers and look forward to working together to continue to scale their platform.”.

Symbiotic Capital首席投资官Himani Bhalla表示，“Symbiotic很高兴支持Caresyntax通过其创新平台提高手术效果，为整个医疗生态系统的利益相关者提供利益。Caresyntax在医院、医疗技术和保险公司的发展给我们留下了深刻印象，并期待着共同努力，继续扩大其平台的规模。”。

The Caresyntax platform also addresses critical data shortfall and fragmentation challenges that hinder the progress of precision and data-assisted surgery in the $3 trillion global surgical market. Caresyntax leverages tech and AI to collect, integrate, and analyze unique and comprehensive data, providing caregivers with real-time and long-term clinical decision support that enhances the patient journey, boosts hospital operational efficiency, and drives better patient outcomes and profitability..

Caresyntax平台还解决了关键的数据不足和碎片化挑战，这些挑战阻碍了全球3万亿美元手术市场中精准和数据辅助手术的进展。Caresyntax利用技术和人工智能收集、整合和分析独特而全面的数据，为护理人员提供实时和长期的临床决策支持，从而增强患者旅程，提高医院运营效率，并推动更好的患者预后和盈利能力。。

“MTIP proudly backs the forefront of surgical intelligence through our investment in Caresyntax. What drew us to Caresyntax was not only their stronghold in a rapidly expanding sector but also their unique platform approach, seamlessly integrating workflow software and data-driven solutions. This investment reflects our commitment to supporting innovative solutions that enhance patient care and empower healthcare professionals globally.

“MTIP通过对CareStanx的投资，自豪地支持了外科智能的前沿。吸引我们来到CareStanx的不仅是他们在快速扩张的行业中的据点，还有他们独特的平台方法，无缝集成了工作流软件和数据驱动解决方案。这项投资反映了我们致力于支持创新解决方案，以增强患者护理并赋予全球医疗保健专业人员权力。

Together, we’re driving the future of smarter and safer surgeries, making a meaningful impact on the world.” said Katrin Vatiska, Investment Partner at MTIP..

我们共同推动着更智能、更安全手术的未来，对世界产生了重大影响。”MTIP投资合伙人KatrinVatiska表示。。

With operations that span the US and EMEA, the company is experiencing record demand for its solutions from both private and public hospitals. Its proven record of reducing costs, increasing profitability, and improving patient outcomes has created a unique set of differentiators.

随着业务遍及美国和欧洲、中东和非洲地区，该公司正经历着私人和公立医院对其解决方案的创纪录需求。它在降低成本、提高盈利能力和改善患者预后方面的良好记录创造了一系列独特的优势。

Dennis Kogan, Co-Founder and CEO at Caresyntax said, “Together with our partners and investors, we are working towards deploying precision surgical tools, empowered by data and AI, to improve patient outcomes. This financing is not just an investment in Caresyntax, but an investment in the future of surgery.

CareStanx联合创始人兼首席执行官丹尼斯·科根（Dennis Kogan）表示：“我们正与合作伙伴和投资者一起，致力于部署由数据和人工智能授权的精密手术工具，以改善患者的预后。这笔资金不仅是对CareStanx的投资，也是对手术未来的投资。

My gratitude extends to our investors who contribute to and believe in the power of smart data and AI usage in the operating room.”.

我感谢我们的投资者，他们为手术室中智能数据和人工智能的使用做出了贡献，并相信这一点。”。

Since the Company’s 2021 Series C fundraiser, Caresyntax has launched innovative AI products which are being leveraged by care teams internationally and opened new markets relating to insurance underwriting and medtech clinical outcome analysis. Today, Caresyntax is focused on leveraging the value of its install base to drive value for the entire surgical ecosystem..

自公司2021年C系列募捐活动以来，Caresyntax推出了创新的人工智能产品，这些产品正被国际护理团队所利用，并开辟了与保险承保和medtech临床结果分析相关的新市场。今天，Caresyntax专注于利用其安装基础的价值来推动整个外科生态系统的价值。。

This funding follows a successful H1 2024 for Caresyntax, marked by over 75% growth in revenue and increased margins, highlighting the expanding recognition and adoption of Caresyntax’s innovative platform in US and EMEA healthcare systems.

这一资金来源于Caresyntax在2024年上半年取得的成功，收入增长超过75%，利润率增加，突显了Caresyntax创新平台在美国和EMEA医疗保健系统中的认可和采用程度不断提高。

Patrick Pfeffer, CEO at Aescuvest stated, “Caresyntax is uniquely positioned to revolutionize the operating room—presently a black box—by transforming it into a data lake. This transformation is aimed at enhancing surgical procedures to make them smarter, safer, and more broadly accessible.”

Aescuvest首席执行官帕特里克·普费弗（PatrickPfeffer）表示：“Caresyntax的独特定位是通过将手术室转变为数据湖来彻底改变手术室，目前手术室是一个黑匣子。这种转变旨在改进外科手术，使其更智能、更安全、更广泛。”

The capital is being used for scaling customer adoption of surgical software tools and for continued development of the company’s AI and edge-to-cloud applications. The round also enables the Caresyntax M&A strategy, with the company acquiring several US surgical data and technology assets in 2023 and looking to complete several acquisitions in 2024 and going forward..

这笔资金正用于扩大客户对外科软件工具的采用，并用于继续开发该公司的人工智能和边缘到云应用程序。这轮收购还实现了Caresyntax并购战略，该公司于2023年收购了几项美国外科数据和技术资产，并有望在2024年及以后完成几项收购。。

“We are grateful for this significant investment in Caresyntax, which strengthens our balance sheet at an important inflection point for the adoption of digital surgery, AI, and automation tools. The capital enables Caresyntax to deliver increased growth momentum, platform adoption, and customer ROI; it also catalyzes M&A and corporate development opportunities,” said Bjoern von Siemens, CFO and CBO at Caresyntax..

Caresyntax首席财务官和首席预算官比约恩·冯·西门子（Bjoern von Siemens）表示：“我们非常感谢对Caresyntax的这项重大投资，在采用数字手术、人工智能和自动化工具的重要转折点上，它加强了我们的资产负债表。这笔资金使Caresyntax能够提供更大的增长势头、平台采用率和客户投资回报率；它还促进了并购和企业发展机会。”。。

About Caresyntax

关于CareSantax

Caresyntax is on a mission to make surgery smarter and safer, by converging AI-powered software, devices, and clinical services to improve patient outcomes. Our vendor-neutral, precision surgery platform delivers actionable insights to improve patient outcomes.  Our proprietary software and AI platform is capturing and analyzing large volumes of video, audio, images, and device, clinical, and operational data in and around the OR.

Caresyntax的使命是通过融合人工智能驱动的软件、设备和临床服务来改善患者的预后，使手术更加智能和安全。我们的供应商中立的精密手术平台提供了可行的见解，以改善患者的预后。我们的专有软件和AI平台正在捕获和分析手术室及其周围的大量视频、音频、图像和设备、临床和操作数据。

The software and automation platform can be used by the care team live, during a procedure, and accessed by those outside the operating room via the platform’s secured dedicated cloud and telehealth links. The Caresyntax platform provides meta-data insights and real-world evidence (RWE) that help surgeons and teams improve their care, hospital administrators use resources more efficiently, and medical device companies advance products.

该软件和自动化平台可供护理团队在手术过程中使用，并可由手术室以外的人员通过平台的安全专用云和远程医疗链接访问。CareStanx平台提供元数据见解和现实世界证据（RWE），帮助外科医生和团队改善护理，医院管理员更有效地使用资源，医疗设备公司推进产品。

It also supports insurance companies to understand and control risks, as well as enable contracts on a value-based model. Headquartered in San Francisco in the US and in Berlin internationally, Caresyntax software is being used in more than 3,000 operating rooms worldwide and supports surgical teams in more than three million procedures per year..

它还支持保险公司了解和控制风险，并支持基于价值的模型签订合同。Caresyntax软件总部位于美国旧金山和国际柏林，在全球3000多个手术室使用，每年为300多万手术团队提供支持。。

Please contact Caresyntax for any inquiries related to:

有关以下方面的任何查询，请联系Caresyntax：

Digitalization of Operating Rooms (ORs)

手术室数字化

Operating Room (OR) Integration

手术室（OR）集成

Capture and Analysis of Clinical and Video Information

临床和视频信息的捕获和分析

Patient Engagement Software

患者参与软件

Operating Room Efficiency

手术室效率

Perioperative Efficiency

围手术期效率

Surgical Video Analytics

手术视频分析

Impact of AI on Surgical Outcomes

人工智能对手术结果的影响

Innovations in Healthcare Technology and Patient Safety

医疗技术创新与患者安全

Insights into the Future of Data-Driven Surgery and Surgery

洞察数据驱动手术和外科的未来

For more information, visit caresyntax.com.

有关更多信息，请访问caresyntax.com。

Originally announced August 15th, 2024

最初于2024年8月15日宣布

TagsAescuvest BIONIQ Capital Bjoern von Siemens BlackRock Innovation Capital CareSyntax Cure Capital Dennis Kogan Health IT Funding Health IT Fundings Health IT Investment Himani Bhalla Katrin Vatiska Lauxera Capital MTIP AG Optum Ventures Patrick Pfeffer PFM Health Sciences Pictet Alternative Advisors Plug & Play Growth Fund ProAssurance Corp Relyens Group surgical.ai Symbiotic Capital Vesalius Biocapital .

TagsAescuvest BIONIQ Capital Bjoern von Siemens BlackRock Innovation Capital Carestanx Cure Capital Dennis Kogan Health IT Funding Health IT Fundings Health IT Investment Himani Bhalla Katrin Vatiska Lauxera Capital MTIP AG Optum Ventures Patrick Pfeffer PFM Health Sciences Pictet Alternative Advisors Plug&Play Growth Fund ProAssurance Corp Relyens Group surgical.ai Symb。

Get Fresh Healthcare & IT Stories Delivered Daily

每天提供新鲜的医疗保健和IT故事

Join thousands of your healthcare & HealthIT peers who subscribe to our daily newsletter.

加入成千上万订阅我们每日新闻稿的healthcare&HealthIT同行。

We respect your privacy and will never sell or give out your contact information

我们尊重您的隐私，绝不出售或泄露您的联系信息